Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) EBITDA: 2018-2025

Historic EBITDA for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Sep 2025 value amounting to -$13.4 million.

  • Arcturus Therapeutics Holdings' EBITDA fell 94.81% to -$13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.7 million, marking a year-over-year decrease of 6.49%. This contributed to the annual value of -$80.9 million for FY2024, which is 172.30% down from last year.
  • Per Arcturus Therapeutics Holdings' latest filing, its EBITDA stood at -$13.4 million for Q3 2025, which was down 46.49% from -$9.2 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' 5-year EBITDA high stood at $117.3 million for Q4 2022, and its period low was -$56.3 million during Q1 2021.
  • Moreover, its 3-year median value for EBITDA was -$14.1 million (2025), whereas its average is -$13.4 million.
  • In the last 5 years, Arcturus Therapeutics Holdings' EBITDA slumped by 476.31% in 2021 and then spiked by 403.51% in 2022.
  • Arcturus Therapeutics Holdings' EBITDA (Quarterly) stood at -$38.7 million in 2021, then spiked by 403.51% to $117.3 million in 2022, then crashed by 109.98% to -$11.7 million in 2023, then tumbled by 156.30% to -$30.0 million in 2024, then plummeted by 94.81% to -$13.4 million in 2025.
  • Its EBITDA was -$13.4 million in Q3 2025, compared to -$9.2 million in Q2 2025 and -$14.1 million in Q1 2025.